Valeo Chalks Up Another Milestone For Canadian Enoxaparin Biosimilars
Follows Backing To Be Listed On The Quebec Public Health Plan
Executive Summary
Canada’s Valeo Pharma insists it has “worked tirelessly to ensure a robust supply of Redesca,” after completing another milestone for the company’s enoxaparin biosimilar product.
You may also be interested in...
Enoxaparin Biosimilar Makes It Six For Sandoz Canada
Sandoz Canada has taken another “important step as we pursue our ambition to become the leading biosimilars and generics company” with the launch of biosimilar enoxaparin.
Valeo Pharma To Launch Enoxaparin In Canada Early Next Year
Canadian firm Valeo Pharma is looking to make a splash with enoxaparin biosimilars, Redesca and Redesca HP, following approval from Health Canada.
What’s Next? Five Things To Look Out For In October
A busy October will include planned biosimilar launches and key appointments for the off-patent sector.